(MENAFN- Evertise Digital)
-< />
The Inflammatory Bowel Disease (IBD) Drugs Market is projected to reach a valuation of USD 27.65 billion by 2031, experiencing a compound annual growth rate (CAGR) of 3.47% from 2024 to 2031. This growth is primarily driven by the rising prevalence of ulcerative colitis and Crohn's disease worldwide, increasing adoption of biological drugs, and the presence of a strong product pipeline with promising candidates in the development stage.
Inflammatory Bowel Disease Drugs Market List of Inflammatory Bowel Disease Drugs Companies Profiled in Report:
AbbVie Inc Biogen Takeda Pharmaceutical Company Limited Novartis AG Pfizer Inc Lilly UCB S.A. Johnson & Johnson Services Inc. CELLTRION INC Bristol-Myers Squibb Company Merck & Co., Inc.
Free Sample Report of Inflammatory Bowel Disease Drugs Market @
IBD Drugs Market Poised for Growth Fueled by Rising Disease Prevalence and Innovation
Diagnoses of ulcerative colitis and Crohn's disease are climbing worldwide. In the US alone, over 1.6 million people battle these conditions, with an estimated 70,000 new cases identified annually (Crohn's & Colitis Foundation of America). Similar trends are observed in other regions like Australia (RAH Research Fund). This growing patient pool signifies a rising demand for effective treatment solutions. The Indian Journal of Gastroenterology (2023) reports that over 0.3% of the global population suffers from IBD, highlighting its significant impact on global health.
Greater public awareness regarding the benefits of biologics, corticosteroids, and other therapies is driving their global adoption. Research by Science Direct found that in South America, 36.4% of Crohn's disease patients and 9.1% of ulcerative colitis patients utilized biological therapy.
The Future Of IBD Treatment Is Bright With A Strong Product Pipeline
AbbVie's ABBV-154 (anti-TNF GRM ADC) and Lilly's Mirikizumab (large molecule) are examples of upcoming advancements expected to hit the market soon. Current therapies focus on curbing inflammation, minimizing complication risks, and achieving long-term remission.
The Embrace Of Technology Is Another Exciting Trend
Leading players are actively incorporating AI into drug discovery for IBD, paving the way for novel treatment regimens for Crohn's disease and ulcerative colitis. Collaborative efforts between pharmaceutical giants and tech innovators like the partnership between CytoReason (AI tech) and Ferring Pharmaceuticals are accelerating the development of innovative therapeutics.
Single-cell RNA sequencing is revolutionizing IBD treatment. This technology allows healthcare professionals to delve deeper into the disease's molecular basis. Examples include The University of California and VA San Diego Healthcare System's (August 2020) use of transcriptomic and antigen receptor sequencing to study immune cell features in individuals with and without ulcerative colitis. These advancements facilitate the development of novel therapies, personalized medicine approaches, and even disease prevention strategies.
Furthermore, strategic maneuvers by key players, including product launches, expansions, collaborations, and development efforts, are expected to further propel market growth. Acquisitions like AbbVie' s purchase of Allergan in 2020 exemplify this trend and contribute to a more diverse product portfolio for IBD treatment. The increasing adoption of novel products and large molecules paints a promising picture for the future of the IBD drugs market.
The focus on enhancing treatment options continues, with companies and organizations actively initiating clinical research. Verily's partnership with the Crohn's & Colitis Foundation in October 2022 to build a longitudinal registry exemplifies this trend and is expected to accelerate research efforts. A strong pipeline of potential new medications like Roivant Sciences' RVT-3101 (targeting TL1A) for ulcerative colitis signifies the industry's commitment to innovation.
Have Any Query? Ask Our Experts @
Inflammatory Bowel Disease Drugs Industry Segmentation as Follows:
By Type
Ulcerative Colitis Crohn's Disease
By Drug Class
TNF inhibitors Corticosteroids Aminosalicylates JAK inhibitors Anti-integrin IL inhibitors
By Distribution Channel
Hospital Pharmacy Drug Store Retail Pharmacy Online Pharmacy
The Crohn's Disease Segment Dominated The Market In 2023 With A 63%
This dominance can be attributed to the rising prevalence of Crohn's disease, the high cost associated with its treatment, and surging prescription rates of biologics. Moreover, the introduction of promising pipeline candidates like Skyrizi IV, approved by the European Commission in November 2022 for moderate to severe Crohn's disease treatment, is anticipated to further bolster segment growth.
In terms of distribution channels , hospital pharmacies held the largest share (48%) in 2023. This dominance is primarily driven by factors such as high hospitalization rates, increasing disease severity, and a growing geriatric population. Additionally, improvements in reimbursement policies for high-priced IBD therapeutics in developed and developing economies are expected to propel segment growth.
North America Dominated The IBD Drugs Market In 2023, Capturing A 42% Share
Biologics are widely adopted for IBD treatment in this region. Also, favorable reimbursement policies ease the financial burden of these medications. Thirdly, the prevalence of ulcerative colitis and Crohn's disease is on the rise in the US and Canada. Finally, strategic acquisitions, like Merck' s purchase of Prometheus Biosciences in April 2023, are strengthening the IBD treatment portfolios of key companies in the region. Europe follows as the second-largest market, driven by a growing population seeking IBD treatment and the availability of diverse treatment options. The Asia Pacific region is anticipated to witness the highest growth rate due to increasing awareness about IBD and growing approvals for new drugs. For instance, EA Pharma received approval for CAROGRA in Japan for treating ulcerative colitis in March 2022.
Key Takeaways from this Inflammatory Bowel Disease Drugs Market Study
Gain insights into a market expected to surpass USD 27.65 billion by 2031, fueled by rising IBD prevalence and a robust pipeline of new drugs. Identify key growth drivers like rising adoption of biologics, technological advancements in drug discovery, and increasing government support for IBD treatment. Explore lucrative opportunities for pharmaceutical companies to develop and commercialize novel and improved IBD treatment options. Understand the dominance of North America, the growth potential of Asia Pacific, and the established market of Europe in the IBD drugs market. Be informed of potential challenges like geopolitical tensions and economic downturns, and strategize to mitigate their impact.
Purchase Inflammatory Bowel Disease Drugs Market Report @
About US:
SNS Insider has been a leader in data and analytics globally with its authentic consumer and market insights. The trust of our clients and business partners has always been at the center of who we are as a company. We are a business that leads the industry in innovation, and to support the success of our clients, our highly skilled engineers, consultants, and data scientists have consistently pushed the limits of the industry with innovative methodology and measuring technologies.
We assist our clients to anticipate industrial, economic, and consumer trends to drive disruptive change by fusing global experience with local information from experts throughout the world. We bring context to strategic and tactical data by bridging approaches based on data science and field research, assisting you in addressing your most pressing problems and spotting possibilities.
Contact Us:
Akash Anand – Head of Business Development & Strategy,
...,
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND),
Website:
MENAFN12052024005025011514ID1108202181
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.